Seagen and Zai Lab ink part­ner­ship on Tiv­dak ex­pan­sion in­to Chi­na and sur­round­ing ar­eas; NC biotech snaps up seed ...

3 years ago
News Briefing

Con­text Ther­a­peu­tics trims pipeline, cuts down on spend­ing to con­serve cash

3 years ago
R&D

Aque­s­tive touts PhII da­ta — and speed — in po­ten­tial EpiPen re­place­ment can­di­date

3 years ago
R&D

George Church’s wool­ly mam­moth re­vival biotech Colos­sal spins out com­pu­ta­tion­al bio out­fit

3 years ago
Financing
Startups

Emer­gent clos­es on buy­ing small­pox drug Tem­bexa from Chimerix with a $238M pay­ment

3 years ago
Deals
Pharma

Now play­ing catch-up to blue­bird, Ver­tex and CRISPR send in their pitch for blood dis­or­der cell ther­a­py

3 years ago
Cell/Gene Tx
FDA+

FDA slaps a par­tial hold on Avid­i­ty's mAb-siR­NA ther­a­py, paus­ing en­roll­ment in mus­cle weak­ness dis­ease study

3 years ago
R&D
FDA+

Com­plete­ly clean FDA-in­dus­try user fee deal at­tached to a must-pass gov­ern­ment spend­ing bill

3 years ago
FDA+

Ar­se­nal­Bio lands $70M cash deal with can­cer gi­ant Genen­tech to de­vel­op cell ther­a­py

3 years ago
Deals
Cell/Gene Tx

In sur­vival mode, Ex­i­cure cuts to the bone — paus­ing all R&D and chop­ping head­count by 66%

3 years ago
People
R&D

Bio­gen pays $900M to set­tle wide-rang­ing physi­cian kick­back claims

3 years ago
Pharma
Law

Sanofi turns to a Jen­nifer Doud­na gene edit­ing up­start for next-gen NK cell al­liance

3 years ago
Deals

Even as pan­dem­ic re­cedes, short-staffed tri­al sites leave can­cer pa­tients wait­ing

3 years ago
R&D
Pharma

New drug price law could help Part D en­rollees who can't fill can­cer treat­ments due to costs, White House says

3 years ago
Law

Ipsen be­comes the lat­est phar­ma to ex­pand in Ire­land, with a $50M in­vest­ment in its fa­cil­i­ty in Dublin sub­urbs

3 years ago
Pharma
Manufacturing

'Not alone': Te­va grows aware­ness cam­paign for com­mon Hunt­ing­ton's side ef­fect

3 years ago
Pharma
Marketing

My­ovant launch­es new pa­tient sto­ry­telling plat­form, de­buts with video se­ries on prostate can­cer

3 years ago
Pharma
Marketing

Three with­drawals in ad­vanced ovar­i­an can­cer spell trou­ble for PARP class

3 years ago
Pharma
FDA+

Over­worked and ready for ex­pan­sion: FDA's cell and gene ther­a­py of­fice preps to add about 100 new po­si­tions

3 years ago
Cell/Gene Tx
FDA+

Lipocine shifts fo­cus to CNS; Drug ap­proval trig­gers cap­i­tal in­fu­sion at Fen­nec

3 years ago
News Briefing

Seagen tees up with Dutch I/O out­fit, en­gi­neers $700M deal for EGFR as­set

3 years ago
Deals

Ar­cutis' for­mu­la­tion of old As­traZeneca drug clears an­oth­er PhI­II test

3 years ago
R&D

FDA's top gener­ic drug leader puts in her two weeks as GDU­FA III looms

3 years ago
People
FDA+

Val­ne­va’s sec­ond-gen Covid vac­cine plans up in the air as it looks for part­ner

3 years ago
Coronavirus
First page Previous page 455456457458459460461 Next page Last page
A service from the Financial Times